What is Nuclera?
Headquartered in Cambridge, UK, Nuclera is transforming the landscape of biological research through its proprietary eProtein desktop bioprinting technology. Founded in 2013 by University of Cambridge PhD graduates, the company addresses the critical bottleneck of protein inaccessibility that has long hindered scientific progress. By enabling researchers to produce proteins on-demand, Nuclera empowers laboratories to bypass traditional, time-consuming supply chains. The company operates at the intersection of hardware engineering and synthetic biology, positioning itself as an essential infrastructure provider for the next generation of drug discovery and biotechnology development.
How much funding has Nuclera raised?
Nuclera has raised a total of $157.6M across 5 funding rounds:
Series A
$11.2M
Series B
$58M
Grant
$1.4M
Series C
$75M
Series C
$12M
Series A (2018): $11.2M with participation from RT Partners
Series B (2022): $58M led by RT Partners, Verve Ventures, Amadeus Capital Partners, Jonathan Milner, E Ink, Future Planet Capital, and M&G
Grant (2024): $1.4M supported by UK Research & Innovation
Series C (2024): $75M featuring Cambridge Innovation Capital, Elevage Medical Technologies, British Patient Capital, and Patient Square Capital
Series C (2026): $12M backed by G K Goh Holdings, Elevage Medical Technologies, and British Business Bank
Key Investors in Nuclera
Patient Square Capital
A specialized investment firm focused exclusively on the healthcare industry, providing strategic capital to companies that aim to improve patient outcomes and advance medical innovation.
Cambridge Innovation Capital
A leading venture investor with deep ties to the University of Cambridge, dedicated to supporting high-growth entrepreneurs in the life sciences and deep tech sectors.
Elevage Medical Technologies
An investment firm that supports medical technology companies through capital and operational expertise to accelerate innovation in diagnostics and health-improving tools.
What's next for Nuclera?
With the successful closure of this latest funding round, Nuclera is poised to scale its manufacturing capabilities and broaden its market reach. The strategic focus will likely shift toward enhancing the throughput of its eProtein platform and deepening its integration within the global pharmaceutical R&D pipeline. As the company transitions from a development-focused entity to a commercial-scale enterprise, the emphasis will remain on maintaining its competitive advantage in desktop bioprinting while exploring new applications for its protein synthesis technology. The continued support from specialized healthcare and deep tech investors provides the necessary runway to sustain long-term innovation and solidify Nuclera's market leadership.
See full Nuclera company page
